Merck KGaA: beats consensus in Q2
(CercleFinance.com) - Merck KGaA announces adjusted EPS (excluding extraordinary items) that is up 25.
2% at 1.54 euro for Q2, beating the consensus by 10 cents, with adjusted EBITDA that is up 23.8% at 1.1 million euros (+20.3% in organic terms).
The German health and chemicals group's revenues increased by 6.9% to 4 billion euros, including organic growth of 5.6%, to which all regions contributed, particularly Asia-Pacific.
Merck KgaA has confirmed its FY 2019 targets, including 10% to 13% organic growth in adjusted EBITDA, with 3% to 5% sales growth, as well as adjusted EPS of around 5.30 euros to 5.65 euros.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
2% at 1.54 euro for Q2, beating the consensus by 10 cents, with adjusted EBITDA that is up 23.8% at 1.1 million euros (+20.3% in organic terms).
The German health and chemicals group's revenues increased by 6.9% to 4 billion euros, including organic growth of 5.6%, to which all regions contributed, particularly Asia-Pacific.
Merck KgaA has confirmed its FY 2019 targets, including 10% to 13% organic growth in adjusted EBITDA, with 3% to 5% sales growth, as well as adjusted EPS of around 5.30 euros to 5.65 euros.
Copyright (c) 2019 CercleFinance.com. All rights reserved.